Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Tecvayli and Hernexeos might get speedy approval decisions.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The line-up is revealed to include Merck & Co and J&J itself.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A phase 1 study of OKI-219 reads out imminently.
Bristol will test the bispecific in two new lung indications.
